Abstract 233P
Background
Protein polybromo-1 (PB1) encoded by the PBRM1 gene is involved in chromatin-remodeling processes as a part of the SWI/SNF complex. Pathogenic variants of PBRM1 gene are commonly encountered in ccRCC. Much attention has been drawn to the predictive potential of PBRM1 to immunotherapeutic agents’ response in solid tumors. This work aims to establish an interconnection between PBRM1 loss and TIME of ccRCC.
Methods
The ccRCC cohort was obtained from the Cancer Genome Atlas Program (TCGA). Patients were stratified based on the presence of PBRM1 pathological variants into wild type group (n = 213) or mutant group (n = 153). TIME was evaluated through the enrichment of immunological processes-related gene sets using gene set enrichment analysis (GSEA) within the hallmarks of cancer and ontology gene sets. A gene set was considered significantly enriched with a P-value < .05 and a false discovery rate (FDR) ≤ 0.25. Immune cells infiltration was explored using precalculated infiltration scores of xCell. T-cell dysfunction score was obtained from TIDE server.
Results
GSEA illustrated enrichments in three immunological sets within the hallmarks of cancer, including TNF-α signaling through NF-κB (enrichment score (ES) = 0.43, Q value < .001, FDR = 0.007), INF-α response (ES = 0.34, Q value = .03, FDR = 0.190), and INF-γ response (ES = 0.39, Q value < .001, FDR = 0.022). Gene ontology sets screening highlighted the effect of PBRM1 loss on CXCR chemokine receptor binding (ES = 0.75, Q value < .001, FDR = 0.202) with no enriched sets within the cellular component or biological process sections. The mutant group showed a significant CD8+ T-cells depletion alongside reduced infiltration of eosinophils, cancer-associated fibroblasts, M1 macrophages, and T helper 2 cells. PBRM1 damage did not induce a T-cell dysfunction (z score = 0.726, P = .468). In addition, PBRM1 loss was correlated with a superior response to nivolumab in a cohort of 35 patients (fold change = 58.7 and P = .0123).
Conclusions
PBRM1 Loss induces global transcription alternations that impact many immunological processes. Such phenomena could be associated with the positive correlation to immunotherapy response in ccRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract